A brain-computer interface that allowed a man, 45, with ALS to communicate using recordings of his own voice has won a $7,500 ...

Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...

The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...

Columnist Dagmar Munn shares the strategy that helps her get unstuck when she's not feeling motivated. Time is precious with ...

While life with ALS brings continued disease progression, columnist Kristin Neva is encouraged by signs of renewal outdoors.

Columnist Juliet Taylor explains how her goals and priorities dramatically shifted while living with her late husband's ALS.

RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP) for people with ...

A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...

The first patient has been dosed in a Phase 1 clinical study testing AMX0114, an experimental therapy being developed by Almylyx Pharmaceuticals for amyotrophic lateral sclerosis (ALS). The treatment ...